levodopa and f 13640
levodopa has been researched along with f 13640 in 6 studies
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bardin, L; Cenci, MA; Depoortère, R; Iderberg, H; Kleven, MS; Koek, W; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Brys, I; Halje, P; Newman-Tancredi, A; Petersson, P; Scheffer-Teixeira, R; Varney, M | 1 |
| Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A | 1 |
| Beardsley, PM; Bergman, J; Depoortère, R; Desai, RI; Newman-Tancredi, A; Paronis, CA; Varney, MA; Walentiny, DM | 1 |
| Bouillot, C; Chaib, S; Depoortere, R; Levigoureux, E; Newman-Tancredi, A; Vidal, B; Zimmer, L | 1 |
Other Studies
6 other study(ies) available for levodopa and f 13640
| Article | Year |
|---|---|
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Levodopa; Movement; Neurotransmitter Agents; Oxidopamine; Piperidines; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin Syndrome; Swimming; Vocalization, Animal | 2015 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2016 |
Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT
Topics: Animals; Basal Ganglia; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Electric Stimulation; Evoked Potentials; Female; Levodopa; Neural Pathways; Parkinson Disease, Secondary; Piperazines; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thalamus | 2018 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Serotonin 5-HT1 Receptor Agonists | 2020 |
NLX-112, a highly selective 5-HT
Topics: Animals; Humans; Levodopa; Macaca; Male; Piperidines; Pyridines; Rats; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2022 |
Multimodal imaging study of the 5-HT
Topics: Animals; Dyskinesias; Fluorodeoxyglucose F18; Levodopa; Multimodal Imaging; Parkinson Disease; Rats; Receptor, Serotonin, 5-HT1A; Serotonin | 2023 |